Efrem Kamen
Adjunct Professor @ Columbia Business School
New York, United States
Efrem Kamen is a Series B investor at Columbia Business School in New York focused on Biotechnology and Health Care. Efrem Kamen is the Adjunct Professor at Columbia Business School. Efrem Kamen attended Columbia University in the City of New York.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Efrem Kamen invests in
Stages Efrem Kamen invests in
Countries Efrem Kamen invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (60%)
- Health Care 2 (40%)
- Medical 1 (20%)
- Diabetes 1 (20%)
- Life Science 1 (20%)
Stage
- Series B 1 (20%)
- Series C 1 (20%)
- Series D 1 (20%)
- Post-IPO Equity 1 (20%)
- Convertible Note 1 (20%)
Country
- United States 2 (40%)
- Germany 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Beta Bionics
|
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in aready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States. | $100M / Series D / Aug 30, 2023 | |
Sonendo
|
Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System. | $63M / Post-IPO Equity / Sep 23, 2022 | |
|
Beta Bionics
|
Beta Bionics is a biotechnology company that develops an integrated bionic pancreas system called the iLet. The iLet Bionic Pancreas System was granted breakthrough designation in all configurations (insulin-only, glucagon-only, and bihormonal), including use with Zealand Pharma’s dasiglucagon, a glucagon analog with a unique stability profile in aready-to-use aqueous solution. It also offers a bionic pancreas device for glucose metabolism to the diabetes community.Beta Bionics was founded in 2015 and is based in Boston, Massachusetts, United States. | $57M / Series C / Feb 17, 2022 | |
AtaiBeckley
|
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in themental health space.ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany. | $25M / Convertible Note / Apr 27, 2020 | |
|
AtaiBeckley
|
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in themental health space.ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany. | $43M / Series B / Mar 01, 2019 |
Co-Investors
About Columbia Business School
Columbia Business School was first founded in 1916, thanks in part to a generous gift from the banking executive Emerson McMillin. There were 11 faculty members on our initial staff, teaching an inaugural class of 61, including eight women. Today, as the School has evolved to meet the needs of an ever-changing business world, both our numbers andour reach have multiplied. Columbia Business School is an ivy league school. In addition to the Full-Time MBA, the School now offers several Executive MBA options, as well as doctoral and master of science degrees and robust Executive Education opportunities. Throughout this evolution, we have maintained an unwavering commitment to improving the world of business through cutting-edge research, innovative education, and an expanding global network.
Columbia Business School Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bill O'Farrell
Professor
|
|||
|
Efrem Kamen
Adjunct Professor
|
|||
Richard Zannino
Executive-in- Residence
|
|||
Adam Quinton
Adjunct Professor
|
|||
Alan Canarslan
MBA Graduate
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Efrem Kamen invest in?
Efrem Kamen invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Efrem Kamen?
Public channels for Efrem Kamen include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Efrem Kamen last invest?
The most recent investment recorded for Efrem Kamen closed in Aug 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
